1
|
Stöllberger C, Finsterer J. Correlation between pathoanatomic findings, imaging modalities, and genetic findings in patients with left ventricular hypertrabeculation/noncompaction. Expert Rev Cardiovasc Ther 2021; 19:595-606. [PMID: 34053374 DOI: 10.1080/14779072.2021.1937128] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Introduction: Left ventricular hypertrabeculation, also named 'noncompaction' (LVHT) is a cardiac abnormality which is detected by pathoanatomic investigation or during cardiac surgery. Imaging techniques visualize LVHT by ventriculography, echocardiography, cardiac magnetic resonance imaging (CMRI) and computed tomography (CT).Areas covered: We aimed to assess 1) how often the definition of LVHT was validated against a criterion standard, 2) if inter- and intra-observer agreement was assessed, and 3) how often LVHT was associated with genetic diseases. A literature search disclosed 58 cases whose hearts were investigated pathoanatomically and by ≥1 imaging technique. Echocardiography was most frequently (95%) compared with pathoanatomy, followed by cMRI (31%), ventriculography (7%) and CT (5%). Intra- and inter-observer agreement was more frequently assessed for cMRI definitions and yielded more consistent results than for echocardiographic definitions. Since genetic findings were only reported from 4 of the 58 cases, no association with imaging findings could be carried out.Expert opinion: Correlation between pathoanatomic investigations with imaging techniques will hopefully contribute to reliable and uniformly accepted definitions of LVHT. Most probably, the echocardiographic definition of LVHT will be a synthesis of the currently used definitions, integrating short axis and four-chamber views. A refinement of cMRI definitions, considering pathoanatomic and echocardiographic investigations, seems necessary to avoid overdiagnosis.
Collapse
|
2
|
Stöllberger C, Finsterer J. Understanding left ventricular hypertrabeculation/noncompaction: pathomorphologic findings and prognostic impact of neuromuscular comorbidities. Expert Rev Cardiovasc Ther 2018; 17:95-109. [PMID: 30570401 DOI: 10.1080/14779072.2019.1561280] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
INTRODUCTION When >3 trabeculations associated with interventricular recesses are found, this is termed 'left ventricular hypertrabeculation/noncompaction' (LVHT). Cardiac-imaging methods detect LVHT in all ages, isolated or associated with extracardiac, especially neuromuscular disorders (NMDs). Many issues about LVHT are unclear. The review gives an update about pathomorphologic findings in patients >14 years and the role of NMDs in LVHT. Areas covered: A PubMed-search for the terms "noncompaction" or "non-compaction" or "hypertrabeculation" AND "autopsy" or 'biopsy' or 'ultrastructure' or 'electron microscopy' AND 'neuromuscular' or 'myopathy' or 'neuropathy' was carried out from 1985 to July 2018. Expert commentary: Macroanatomic (n = 65), histopathologic (n = 59) and ultrastructural (n = 7) reports were found. A comparison with echocardiography was described in 45 cases. Measurements of non-compacted and compacted layer were only given from hearts investigated in short-axis cuts after formaldehyde-fixation. Endocardial, subendocardial and interstitial fibrosis were frequent findings. When LVHT-patients were systematically investigated, a NMD was found in 80%, most frequently mitochondrial disorders, Barth syndrome, zaspopathy, and myotonic dystrophy type 1. LVHT does not seem to be a special type of cardiac involvement of NMDs. NMDs affect prognosis in LVHT as well as LVHT affects prognosis in patients with Duchenne muscular dystrophy.
Collapse
Affiliation(s)
- Claudia Stöllberger
- a 2nd Medical Department with Cardiology and Intensive Care Medicine , Rudolfstifung Hospital , Vienna , Austria
| | - Josef Finsterer
- b Rudolfstiftung Hospital , Danube University Krems , Vienna , Austria
| |
Collapse
|
3
|
Cramer SC. Treatments to Promote Neural Repair after Stroke. J Stroke 2018; 20:57-70. [PMID: 29402069 PMCID: PMC5836581 DOI: 10.5853/jos.2017.02796] [Citation(s) in RCA: 65] [Impact Index Per Article: 10.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2017] [Revised: 01/16/2018] [Accepted: 01/18/2018] [Indexed: 12/12/2022] Open
Abstract
Stroke remains a major cause of human disability worldwide. In parallel with advances in acute stroke interventions, new therapies are under development that target restorative processes. Such therapies have a treatment time window measured in days, weeks, or longer and so have the advantage that they may be accessible by a majority of patients. Several categories of restorative therapy have been studied and are reviewed herein, including drugs, growth factors, monoclonal antibodies, activity-related therapies including telerehabilitation, and a host of devices such as those related to brain stimulation or robotics. Many patients with stroke do not receive acute stroke therapies or receive them and do not derive benefit, often surviving for years thereafter. Therapies based on neural repair hold the promise of providing additional treatment options to a majority of patients with stroke.
Collapse
Affiliation(s)
- Steven C. Cramer
- Departments of Neurology, Anatomy & Neurobiology and Physical Medicine & Rehabilitation, University of California, Irvine, CA, USA
| |
Collapse
|
4
|
Hanes DW, Wong ML, Jenny Chang CW, Humphrey S, Grayson JK, Boyd WD, Griffiths LG. Embolization of the first diagonal branch of the left anterior descending coronary artery as a porcine model of chronic trans-mural myocardial infarction. J Transl Med 2015; 13:187. [PMID: 26047812 PMCID: PMC4634919 DOI: 10.1186/s12967-015-0547-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2015] [Accepted: 05/25/2015] [Indexed: 12/24/2022] Open
Abstract
Background Although the incidence of acute death related to coronary artery disease has decreased with the advent of new interventional therapies, myocardial infarction remains one of the leading causes of death in the US. Current animal models developed to replicate this phenomenon have been associated with unacceptably high morbidity and mortality. A new model utilizing the first diagonal branch of the left anterior descending artery (D1-LAD) was developed to provide a clinically relevant lesion, while attempting to minimize the incidence of adverse complications associated with infarct creation. Methods Eight Yucatan miniature pigs underwent percutaneous embolization of the D1-LAD via injection of 90 µm polystyrene micro-spheres. Cardiac structure and function were monitored at baseline, immediately post-operatively, and at 8-weeks post-infarct using transthoracic echocardiography. Post-mortem histopathology and biochemical analyses were performed to evaluate for changes in myocardial structure and extracellular matrix (ECM) composition respectively. Echocardiographic data were evaluated using a repeated measures analysis of variance followed by Tukey’s HSD post hoc test. Biochemical analyses of infarcted to non-infarcted myocardium were compared using analysis of variance. Results All eight pigs successfully underwent echocardiography prior to catheterization. Overall procedural survival rate was 83% (5/6) with one pig excluded due to failure of infarction and another due to deviation from protocol. Ejection fraction significantly decreased from 69.7 ± 7.8% prior to infarction to 50.6 ± 14.7% immediately post-infarction, and progressed to 48.7 ± 8.9% after 8-weeks (p = 0.011). Left ventricular diameter in systole significantly increased from 22.6 ± 3.8 mm pre-operatively to 30.9 ± 5.0 mm at 8 weeks (p = 0.016). Histopathology showed the presence of disorganized fibrosis on hematoxylin and eosin and Picro Sirius red stains. Collagen I and sulfated glycosaminoglycan content were significantly greater in the infarcted region than in normal myocardium (p = 0.007 and p = 0.018, respectively); however, pyridinoline crosslink content per collagen I content in the infarcted region was significantly less than normal myocardium (p = 0.048). Conclusion Systolic dysfunction and changes in ECM composition induced via embolization of the D1-LAD closely mimic those found in individuals with chronic myocardial infarction (MI), and represents a location visible without the need for anesthesia. As a result, this method represents a useful model for studying chronic MI. Electronic supplementary material The online version of this article (doi:10.1186/s12967-015-0547-4) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Derek W Hanes
- Department of Veterinary Medicine and Epidemiology, University of California, Davis, One Shields Ave., Davis, CA, 95616, USA.
| | - Maelene L Wong
- Department of Veterinary Medicine and Epidemiology, University of California, Davis, One Shields Ave., Davis, CA, 95616, USA.
| | - C W Jenny Chang
- Department of Veterinary Medicine and Epidemiology, University of California, Davis, One Shields Ave., Davis, CA, 95616, USA.
| | - Sterling Humphrey
- University of California Davis, Medical Center, 2221 Stockton Blvd, Sacramento, CA, 95817, USA.
| | - J Kevin Grayson
- Clinical Investigation Facility, David Grant USAF Medical Center, 101 Bodin Circle, Travis AFB, CA, 94535, USA.
| | - Walter D Boyd
- University of California Davis, Medical Center, 2221 Stockton Blvd, Sacramento, CA, 95817, USA.
| | - Leigh G Griffiths
- Department of Veterinary Medicine and Epidemiology, University of California, Davis, One Shields Ave., Davis, CA, 95616, USA.
| |
Collapse
|
5
|
Jiang Y, Chang P, Pei Y, Li B, Liu Y, Zhang Z, Yu J, Zhu D, Liu X. Intramyocardial injection of hypoxia-preconditioned adipose-derived stromal cells treats acute myocardial infarction: an in vivo study in swine. Cell Tissue Res 2014; 358:417-32. [PMID: 25135062 DOI: 10.1007/s00441-014-1975-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Accepted: 07/23/2014] [Indexed: 12/21/2022]
Abstract
Hypoxic preconditioning is a promising method for improving the anti-apoptotic and paracrine signaling capabilities of adipose-derived stromal cells (ADSCs). The purpose of this study was to analyze the influence of different hypoxic conditions on ADSCs and the therapeutic effects of hypoxia-preconditioned ADSCs (HPADSCs) on an animal model of myocardial infarction (MI). For the in vitro studies, ADSCs were divided into five groups and cultured in different oxygen concentrations (1, 3, 5, 10, and 21 %). After 24 h, RT-PCR and western blots showed that 3 % oxygen preconditioning could improve the viability and cytokine secretion of the ADSCs. A Matrigel assay indicated that the HPADSC-conditioned medium could stimulate endothelial cells to form capillary-like tubes. For the in vivo studies, MI was induced by coronary occlusion in 24 mature Chinese minipigs. The animals were divided into three groups and treated by intramyocardial injection with vehicle alone (saline group), with 1 × 10(8) ADSCs cultured in normoxic conditions (ADSCs group) or with 1 × 10(8) ADSCs precultured in 3 % oxygen (HPADSCs group). SPECT and echocardiography demonstrated that cardiac function was improved significantly in the HPADSC transplant group compared with the vehicle control group (P < 0.05). Immunofluorescence showed fewer apoptotic cells and more small- to medium-sized vessels in the HPADSC transplantation group (P < 0.05). Three percent oxygen is the optimum preconditioning treatment for ADSCs. HPADSC transplantation can prevent ventricular remodeling and reduce the infarct size.
Collapse
Affiliation(s)
- Yiyao Jiang
- Department of Cardiovascular Surgery, TEDA International Cardiovascular Hospital Cardiovascular Clinical Hospital of Tianjin Medical University, 61# Third Avenue Tianjin Economic Development Area, Tianjin, 300457, China
| | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Pathomorphologic findings in left ventricular hypertrabeculation/noncompaction of adults in relation to neuromuscular disorders. Int J Cardiol 2013; 169:249-53. [DOI: 10.1016/j.ijcard.2013.08.138] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2013] [Revised: 08/12/2013] [Accepted: 08/18/2013] [Indexed: 11/21/2022]
|
7
|
Maureira P, Marie PY, Liu Y, Yu F, Poussier S, Maskali F, Groubatch F, Karcher G, Tran N. Sustained therapeutic perfusion outside transplanted sites in chronic myocardial infarction after stem cell transplantation. Int J Cardiovasc Imaging 2013; 29:809-17. [PMID: 23404382 DOI: 10.1007/s10554-012-0147-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2012] [Accepted: 10/29/2012] [Indexed: 11/29/2022]
Abstract
This study aimed at comparing long-term variations in the perfusion of chronic myocardial infarction (MI) areas after local injections of autologous bone marrow stem cells (BMSCs). 14 coronary ligated rats with transmural chronic MI (4 months) were used: a control group (n = 7) versus a treated group (n = 7) in which (111)In labeled-BMSCs were directly engrafted on MI areas. By using (111)In/(99m)Tc SPECT and Sestamibi gated-SPECT,. left ventricle perfusion and function were monitored in all animals by serial (99m)Tc-Sestamibi pinhole gated-SPECT over a period of 6 months. Post-therapeutic myocardial perfusion improved as early as 48 h following injection in the 2 groups. This benefice was sustained during the 6-month follow-up in the non-engrafted MI-areas from treated rats (at 6-months: +10 ± 5 %), whereas the engrafted ones, as well as the MI areas from control rats, exhibited progressive deterioration over time (at 6-months: -9 ± 10 % and -5 ± 3 %, respectively). Perfusion enhancement of the chronic MI areas treated by BMSCs transplantation is: (1) marked in the following days, presumably because of an unspecific inflammatory reaction, and (2) sustained over the long term but only outside the sites of cell engraftment, suggesting a distant paracrine effect of transplanted cells.
Collapse
Affiliation(s)
- Pablo Maureira
- Faculty of Medicine, School of Surgery, University of Lorraine, 9 Avenue de Forêt de Haye, 54500 Vandoeuvre-lès-Nancy, France.
| | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Finsterer J, Stöllberger C, Grassberger M, Gerger D. Noncompaction in Mitochondrial Myopathy: Visible on Microscopy but Absent on Macroscopic Inspection. Cardiology 2013; 125:146-9. [DOI: 10.1159/000350411] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2013] [Accepted: 02/17/2013] [Indexed: 11/19/2022]
|
9
|
Marta Oliveira S, Martins E, Oliveira A, Pinho T, Gavina C, Faria T, Silva-Cardoso JC, Pereira J, Júlia Maciel M. Cardiac 123I-MIBG scintigraphy and arrhythmic risk in left ventricular noncompaction. REVISTA PORTUGUESA DE CARDIOLOGIA (ENGLISH EDITION) 2012. [DOI: 10.1016/j.repce.2012.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
10
|
Oliveira SM, Martins E, Oliveira A, Pinho T, Gavina C, Faria T, Silva-Cardoso JC, Pereira J, Maciel MJ. Cardiac 123I-MIBG scintigraphy and arrhythmic risk in left ventricular noncompaction. Rev Port Cardiol 2012; 31:247-50. [DOI: 10.1016/j.repc.2012.01.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2011] [Accepted: 09/08/2011] [Indexed: 01/08/2023] Open
|
11
|
Left ventricular hypertrabeculation/noncompaction associated with coronary heart disease and myopathy. Int J Cardiol 2011; 148:e53-5. [DOI: 10.1016/j.ijcard.2009.03.007] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2009] [Accepted: 03/03/2009] [Indexed: 11/20/2022]
|
12
|
van der Spoel TIG, Jansen of Lorkeers SJ, Agostoni P, van Belle E, Gyongyosi M, Sluijter JPG, Cramer MJ, Doevendans PA, Chamuleau SAJ. Human relevance of pre-clinical studies in stem cell therapy: systematic review and meta-analysis of large animal models of ischaemic heart disease. Cardiovasc Res 2011; 91:649-58. [DOI: 10.1093/cvr/cvr113] [Citation(s) in RCA: 185] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/10/2023] Open
|
13
|
Lupu M, Khalil M, Andrei E, Iordache F, Pfannkuche K, Neef K, Georgescu A, Buzila C, Brockmeier K, Maniu H, Hescheler J. Integration Properties of Wharton’s Jelly-derived Novel Mesenchymal Stem Cells into Ventricular Slices of Murine Hearts. Cell Physiol Biochem 2011; 28:63-76. [DOI: 10.1159/000331714] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/18/2011] [Indexed: 02/06/2023] Open
|
14
|
Surface expression of CXCR4 in unrestricted somatic stem cells and its regulation by growth factors. Cell Biol Int 2010; 34:687-92. [PMID: 20196768 DOI: 10.1042/cbi20090415] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Umbilical cord blood-derived USSCs (unrestricted somatic stem cells) have recently been considered as a potential source for stem cell therapy and transplantation due to their characteristics such as easy accessibility, low immunogenicity, self-renewing and multilineage differentiation potential. Stem cell homing is a key factor in successful transplantation, which is regulated by CXCR4 in stem cells. In this study, we evaluated the expression of CXCR4 in USSCs different passages. Moreover, the effect of VEGF (vascular endothelial growth factor) and IGF-1 (insulin-like growth factor 1) on its expression was assessed. It was shown that the expression of CXCR4 in USSCs decreased with the increase in passage number. It was also revealed that VEGF increased surface expression and mRNA level of CXCR4 in USSCs, while IGF-1 decreased its expression. When VEGF and IGF-1 were administered simultaneously, CXCR4 expression was increased, but the expression level was less than VEGF alone. Finally, it was shown that over-expression of CXCR4 enhanced the migratory capacity of USSCs. The increase of CXCR4 expression, here caused by VEGF in USSCs, can improve the efficacy of stem cell therapy and transplantation after long-term culture of stem cells before clinical use.
Collapse
|
15
|
Abstract
According to the World Health Organization classification of cardiomyopathies, left ventricular noncompaction is still an unclassified cardiomyopathy. In 2006, the American Heart Association classified this entity as a primary cardiomyopathy of genetic origin. In 2008, the European Society of Cardiology updated the classification scheme similar to the World Health Organization classification. At present, there is no consensus on the diagnostic criteria, and diagnosis is based on the morphologic features identified by cardiac imaging studies or at autopsy. Due to lack of standardization of the diagnostic criteria and little awareness of this condition among clinicians, the true prevalence of this disease is not clear. There is no specific therapy for this condition. However, it seems prognosis is much better than initially reported. The current status of diagnosis, prognosis, and management of isolated noncompaction in adults is discussed in this review.
Collapse
Affiliation(s)
- Radha J Sarma
- ABIM, Internal Medicine and Cardiovascular Diseases, University of Southern California, Keck School of Medicine, Division of Cardiovascular Medicine, Los Angeles, CA 90033, USA.
| | | | | |
Collapse
|
16
|
Iwasaki H, Kawamoto A, Willwerth C, Horii M, Oyamada A, Akimaru H, Shibata T, Hirai H, Suehiro S, Wnendt S, Fodor WL, Asahara T. Therapeutic Potential of Unrestricted Somatic Stem Cells Isolated from Placental Cord Blood for Cardiac Repair Post Myocardial Infarction. Arterioscler Thromb Vasc Biol 2009; 29:1830-5. [DOI: 10.1161/atvbaha.109.192203] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Objective—
Unrestricted somatic stem cells (USSCs) were successfully identified from human cord blood. However, the efficacy of USSC transplantation for improving left ventricular (LV) function post myocardial infarction (MI) is still controversial.
Methods and Results—
PBS, 1×10
6
human fibroblasts (Fbr), 1×10
5
USSCs (LD), or 1×10
6
USSCs (HD) were transplanted intramyocardially 20 minutes after ligating the LAD of nude rats. Echocardiography and a microtip conductance catheter at day 28 revealed a dose-dependent improvement of LV function after USSC transplantation. Necropsy examination revealed dose-dependent augmentation of capillary density and inhibition of LV fibrosis. Dual-label immunohistochemistry for cardiac troponin-I and human nuclear antigen (HNA) demonstrated that human cardiomyocytes (CMCs) were dose-dependently generated in ischemic myocardium 28 days after USSC transplantation. Similarly, dual-label immunostaining for smooth muscle actin and class I human leukocyte antigen or that for von Willebrand factor and HNA also revealed a dose-dependent vasculogenesis after USSC transplantation. RT-PCR indicated that expression of human-specific genes of CMCs, smooth muscle cells, and endothelial cell markers in infarcted myocardium were significantly augmented in USSC-treated animals compared with control groups.
Conclusions—
USSC transplantation leads to functional improvement and recovery from MI and exhibits a significant and dose-dependent potential for concurrent cardiomyogenesis and vasculogenesis.
Collapse
Affiliation(s)
- Hiroto Iwasaki
- From Stem Cell Translational Research (H.I., A.K., M.H., A.O., H.A., T.A.), Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology, Kobe, Japan; the Department of Cardiovascular Surgery (H.I., T.S., H.H., S.S.), Osaka City University Graduate School of Medicine, Japan; ViaCell Inc (C.W., S.W., W.L.F.), Cambridge, Mass; and the Department of Regenerative Medicine Science (T.A.), Tokai University School of Medicine, Isehara, Japan
| | - Atsuhiko Kawamoto
- From Stem Cell Translational Research (H.I., A.K., M.H., A.O., H.A., T.A.), Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology, Kobe, Japan; the Department of Cardiovascular Surgery (H.I., T.S., H.H., S.S.), Osaka City University Graduate School of Medicine, Japan; ViaCell Inc (C.W., S.W., W.L.F.), Cambridge, Mass; and the Department of Regenerative Medicine Science (T.A.), Tokai University School of Medicine, Isehara, Japan
| | - Christina Willwerth
- From Stem Cell Translational Research (H.I., A.K., M.H., A.O., H.A., T.A.), Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology, Kobe, Japan; the Department of Cardiovascular Surgery (H.I., T.S., H.H., S.S.), Osaka City University Graduate School of Medicine, Japan; ViaCell Inc (C.W., S.W., W.L.F.), Cambridge, Mass; and the Department of Regenerative Medicine Science (T.A.), Tokai University School of Medicine, Isehara, Japan
| | - Miki Horii
- From Stem Cell Translational Research (H.I., A.K., M.H., A.O., H.A., T.A.), Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology, Kobe, Japan; the Department of Cardiovascular Surgery (H.I., T.S., H.H., S.S.), Osaka City University Graduate School of Medicine, Japan; ViaCell Inc (C.W., S.W., W.L.F.), Cambridge, Mass; and the Department of Regenerative Medicine Science (T.A.), Tokai University School of Medicine, Isehara, Japan
| | - Akira Oyamada
- From Stem Cell Translational Research (H.I., A.K., M.H., A.O., H.A., T.A.), Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology, Kobe, Japan; the Department of Cardiovascular Surgery (H.I., T.S., H.H., S.S.), Osaka City University Graduate School of Medicine, Japan; ViaCell Inc (C.W., S.W., W.L.F.), Cambridge, Mass; and the Department of Regenerative Medicine Science (T.A.), Tokai University School of Medicine, Isehara, Japan
| | - Hiroshi Akimaru
- From Stem Cell Translational Research (H.I., A.K., M.H., A.O., H.A., T.A.), Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology, Kobe, Japan; the Department of Cardiovascular Surgery (H.I., T.S., H.H., S.S.), Osaka City University Graduate School of Medicine, Japan; ViaCell Inc (C.W., S.W., W.L.F.), Cambridge, Mass; and the Department of Regenerative Medicine Science (T.A.), Tokai University School of Medicine, Isehara, Japan
| | - Toshihiko Shibata
- From Stem Cell Translational Research (H.I., A.K., M.H., A.O., H.A., T.A.), Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology, Kobe, Japan; the Department of Cardiovascular Surgery (H.I., T.S., H.H., S.S.), Osaka City University Graduate School of Medicine, Japan; ViaCell Inc (C.W., S.W., W.L.F.), Cambridge, Mass; and the Department of Regenerative Medicine Science (T.A.), Tokai University School of Medicine, Isehara, Japan
| | - Hidekazu Hirai
- From Stem Cell Translational Research (H.I., A.K., M.H., A.O., H.A., T.A.), Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology, Kobe, Japan; the Department of Cardiovascular Surgery (H.I., T.S., H.H., S.S.), Osaka City University Graduate School of Medicine, Japan; ViaCell Inc (C.W., S.W., W.L.F.), Cambridge, Mass; and the Department of Regenerative Medicine Science (T.A.), Tokai University School of Medicine, Isehara, Japan
| | - Shigefumi Suehiro
- From Stem Cell Translational Research (H.I., A.K., M.H., A.O., H.A., T.A.), Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology, Kobe, Japan; the Department of Cardiovascular Surgery (H.I., T.S., H.H., S.S.), Osaka City University Graduate School of Medicine, Japan; ViaCell Inc (C.W., S.W., W.L.F.), Cambridge, Mass; and the Department of Regenerative Medicine Science (T.A.), Tokai University School of Medicine, Isehara, Japan
| | - Stephan Wnendt
- From Stem Cell Translational Research (H.I., A.K., M.H., A.O., H.A., T.A.), Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology, Kobe, Japan; the Department of Cardiovascular Surgery (H.I., T.S., H.H., S.S.), Osaka City University Graduate School of Medicine, Japan; ViaCell Inc (C.W., S.W., W.L.F.), Cambridge, Mass; and the Department of Regenerative Medicine Science (T.A.), Tokai University School of Medicine, Isehara, Japan
| | - William L. Fodor
- From Stem Cell Translational Research (H.I., A.K., M.H., A.O., H.A., T.A.), Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology, Kobe, Japan; the Department of Cardiovascular Surgery (H.I., T.S., H.H., S.S.), Osaka City University Graduate School of Medicine, Japan; ViaCell Inc (C.W., S.W., W.L.F.), Cambridge, Mass; and the Department of Regenerative Medicine Science (T.A.), Tokai University School of Medicine, Isehara, Japan
| | - Takayuki Asahara
- From Stem Cell Translational Research (H.I., A.K., M.H., A.O., H.A., T.A.), Institute of Biomedical Research and Innovation/RIKEN Center for Developmental Biology, Kobe, Japan; the Department of Cardiovascular Surgery (H.I., T.S., H.H., S.S.), Osaka City University Graduate School of Medicine, Japan; ViaCell Inc (C.W., S.W., W.L.F.), Cambridge, Mass; and the Department of Regenerative Medicine Science (T.A.), Tokai University School of Medicine, Isehara, Japan
| |
Collapse
|
17
|
Abstract
Myocardial infarction (MI) and stroke are the first and third leading causes of death in the U.S.A. accounting for more than 1 in 3 deaths per annum. Despite interventional and pharmaceutical advances, the number of people diagnosed with heart disease is on the rise. Therefore, new clinical strategies are needed. Cell-based therapy holds great promise for treatment of these diseases and is currently under extensive preclinical as well as clinical trials. The source and types of stem cells for these clinical applications are questions of great interest. Human umbilical cord blood (hUCB) appears to be a logical candidate as a source of cells. hUCB is readily available, and presents little ethical challenges. Stem cells derived from hUCB are multipotent and immunologically naive. Here is a critical literature review of the beneficial effects of hUCB cell therapy in preclinical trials.
Collapse
Affiliation(s)
| | | | - Mohamed A Gaballa
- Center for Cardiovascular Research, Sun Health Research Institute, Sun City, Arizona; Section Chief of Basic Science, Cardiology Section, Banner GoodSam Medical Center, Phoenix, Arizona
| |
Collapse
|
18
|
Finsterer J. Cardiogenetics, neurogenetics, and pathogenetics of left ventricular hypertrabeculation/noncompaction. Pediatr Cardiol 2009; 30:659-81. [PMID: 19184181 DOI: 10.1007/s00246-008-9359-0] [Citation(s) in RCA: 164] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/30/2008] [Accepted: 11/15/2008] [Indexed: 01/28/2023]
Abstract
BACKGROUND Left ventricular hypertrabeculation (LVHT), also known as noncompaction or spongy myocardium, is a cardiac abnormality of unknown etiology and pathogenesis frequently associated with genetic cardiac and noncardiac disorders, particularly genetic neuromuscular disease. This study aimed to review the current knowledge about the genetic or pathogenetic background of LVHT. METHODS A literature review of all human studies dealing with the association of LVHT with genetic cardiac and noncardiac disorders, particularly neuromuscular disorders, was conducted. RESULTS Most frequently, LVHT is associated with mitochondrial disorders (mtDNA, nDNA mutations), Barth syndrome (G4.5, TAZ mutations), hypertrophic cardiomyopathy (MYH7, ACTC mutations), zaspopathy (ZASP/LDB3 mutations), myotonic dystrophy 1 (DMPK mutations), and dystrobrevinopathy (DTNA mutations). More rarely, LVHT is associated with mutations in the DMD, SCNA5, MYBPC3, FNLA1, PTPN11, LMNA, ZNF9, AMPD1, PMP22, TNNT2, fibrillin2, SHP2, MMACHC, LMX1B, HCCS, or NR0B1 genes. Additionally, LVHT occurs with a number of chromosomal disorders, polymorphisms, and not yet identified genes, as well in a familial context. The broad heterogeneity of LVHT's genetic background suggests that the uniform morphology of LVHT not only is attributable to embryonic noncompaction but also may result from induction of hypertrabeculation as a compensatory reaction of an impaired myocardium. CONCLUSIONS Most frequently, LVHT is associated with mutations in genes causing muscle or cardiac disease, or with chromosomal disorders. These associations require comprehensive cardiac, neurologic, and cytogenetic investigations.
Collapse
Affiliation(s)
- Josef Finsterer
- Krankenanstalt Rudolfstiftung, Postfach 20, 1180 Vienna, Austria, Europe.
| |
Collapse
|
19
|
Psaltis PJ, Gronthos S, Worthley SG, Zannettino AC. Cellular Therapy for Cardiovascular Disease Part 1 - Preclinical Insights. Clin Med Cardiol 2008. [DOI: 10.4137/cmc.s571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Affiliation(s)
- Peter J Psaltis
- Cardiovascular Research Centre, Royal Adelaide Hospital; Department of Medicine, University of Adelaide, South Australia, 5000
| | - Stan Gronthos
- Division of Haematology, Institute of Medical and Veterinary Science; Department of Medicine, University of Adelaide, South Australia, 5000
| | - Stephen G Worthley
- Cardiovascular Research Centre, Royal Adelaide Hospital; Department of Medicine, University of Adelaide, South Australia, 5000
| | - Andrew C.W. Zannettino
- Division of Haematology, Institute of Medical and Veterinary Science; Department of Medicine, University of Adelaide, South Australia, 5000
| |
Collapse
|
20
|
Huang ML, Tian H, Wu J, Matsubayashi K, Weisel RD, Li RK. Myometrial cells induce angiogenesis and salvage damaged myocardium. Am J Physiol Heart Circ Physiol 2006; 291:H2057-66. [PMID: 16782844 DOI: 10.1152/ajpheart.00494.2006] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Characteristically, uterine myometrial cells (MCs) are proliferative, inducing angiogenesis within the female reproductive organ. We evaluated whether MCs implanted into myocardium could also induce angiogenesis and restore heart function after injury. MCs were isolated from the adult rat uterus and cultured for three studies: 1) Intracellular VEGF levels were measured in MCs cultured with progesterone (10−11, 10−9, and 10−7M) ( n = 6 tests per group). 2) Blood vessel density was evaluated 8 days after MCs (3 × 106or 6 × 106), smooth muscle cells (SMCs), or endothelial cells ( n = 6 rats per group) were injected with matrigel into the subcutaneous tissue of adult rats. 3) MCs, SMCs (5 × 106/rat), or media were injected into a transmural scar 3 wk after cryoinjury in rat hearts ( n = 12 rats per group), and heart function, blood vessel density, and myocardial scar size and thickness were evaluated 5 wk later. In study 1, cultured MCs expressed VEGF, with levels significantly ( P < 0.05) upregulated by progesterone at an optimal dose of 10−11M. In study 2, MCs injected into the subcutaneous tissue with matrigel induced significantly more blood vessels, especially large-diameter vessels, than did SMCs or endothelial cells ( P < 0.01 for all groups). This angiogenic effect was greatest ( P < 0.01) at higher doses of MCs and was enhanced by progesterone (10−11M). In study 3, MCs implanted into the injured myocardium increased blood vessel density at the implant area, reduced scar size, and improved cardiac function relative to SMCs and media. Overall, MCs induced angiogenesis in vitro and in vivo, prevented cardiac remodeling, and improved heart functional recovery after cardiac injury.
Collapse
Affiliation(s)
- Ming-Li Huang
- MaRS Centre, Toronto Medical Discovery Tower, 3rd Fl., Rm. 702, 101 College St., Toronto, ON, Canada
| | | | | | | | | | | |
Collapse
|
21
|
Nakamura Y, Yasuda T, Weisel RD, Li RK. Enhanced cell transplantation: preventing apoptosis increases cell survival and ventricular function. Am J Physiol Heart Circ Physiol 2006; 291:H939-47. [PMID: 16582022 DOI: 10.1152/ajpheart.00155.2006] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Cell transplantation prevents cardiac dysfunction after myocardial infarction. However, because most implanted cells are lost to ischemia and apoptosis, the benefits of cell transplantation on heart function could be improved by increasing cell survival. To examine this possibility, male Lewis rat aortic smooth muscle cells (SMCs; 4 x 10(6)) were pretreated with antiapoptotic Bcl-2 gene transfection or heat shock and then implanted into the infarcted myocardium of anesthetized, syngenic female rats (n = 23 per group). On the first day after transplantation, apoptotic SMCs were quantified by using transferase-mediated dUTP nick-end labeling staining. On days 7 and 28, grafted cell survival was quantified by using real-time PCR, and heart function was assessed with the use of echocardiography and the Langendorff apparatus. SMCs given antiapoptotic pretreatments exhibited improvements in each measure relative to controls. Apoptosis was reduced in Bcl-2-treated cells relative to all other groups (P < 0.05), whereas survival (P < 0.01) was increased. Heat shock also significantly decreased apoptosis and increased survival relative to control groups (P < 0.05 for group effect), although these effects were less pronounced than in the Bcl-2-treated group. Further, scar areas were reduced in both Bcl-2- and heat shock-treated groups relative to controls (P < 0.05), and fractional area change and cardiac function were greater (P < 0.05 for both measures). These results indicate that antiapoptosis pretreatments reduced grafted SMC loss after transplantation and enhanced grafted cell survival and ventricular function, which was directly related (r = 0.72; P = 0.002) to the number of surviving engrafted cells.
Collapse
Affiliation(s)
- Yoshinobu Nakamura
- Department of Surgery, Division of Cardiac Surgery, Toronto General Research Institute, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada
| | | | | | | |
Collapse
|